WO1996030762A1 - Methode d'identification de composes imitant et amplifiant l'action de l'insuline - Google Patents
Methode d'identification de composes imitant et amplifiant l'action de l'insuline Download PDFInfo
- Publication number
- WO1996030762A1 WO1996030762A1 PCT/US1996/004226 US9604226W WO9630762A1 WO 1996030762 A1 WO1996030762 A1 WO 1996030762A1 US 9604226 W US9604226 W US 9604226W WO 9630762 A1 WO9630762 A1 WO 9630762A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- insulin
- compounds
- cells
- receptor
- activity
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 206
- 229940125396 insulin Drugs 0.000 title claims abstract description 104
- 108090001061 Insulin Proteins 0.000 title claims abstract description 102
- 102000004877 Insulin Human genes 0.000 title claims abstract description 102
- 239000003623 enhancer Substances 0.000 title abstract description 13
- 238000003556 assay Methods 0.000 title description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 43
- 210000004027 cell Anatomy 0.000 claims description 44
- 102000003746 Insulin Receptor Human genes 0.000 claims description 42
- 108010001127 Insulin Receptor Proteins 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 37
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 21
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 20
- 206010012601 diabetes mellitus Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims description 8
- 102000047882 human INSR Human genes 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 5
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 206010017708 Ganglioneuroblastoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 229960003920 cocaine Drugs 0.000 claims description 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims description 2
- 230000006993 memory improvement Effects 0.000 claims description 2
- 208000028591 pheochromocytoma Diseases 0.000 claims description 2
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 16
- 230000009471 action Effects 0.000 abstract description 7
- 230000003278 mimic effect Effects 0.000 abstract description 6
- 230000019491 signal transduction Effects 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 201000010099 disease Diseases 0.000 description 20
- 230000026731 phosphorylation Effects 0.000 description 16
- 238000006366 phosphorylation reaction Methods 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 230000033077 cellular process Effects 0.000 description 8
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000035578 autophosphorylation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- -1 e.g. Substances 0.000 description 4
- 108010042209 insulin receptor tyrosine kinase Proteins 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000002306 biochemical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000004155 insulin signaling pathway Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010022530 Intercapillary glomerulosclerosis Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003893 regulation of appetite Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical class [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 150000003681 vanadium Chemical class 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Definitions
- the invention relates to insulin mimetic and enhancer agents and more specifically to methods of identifying compounds that mimic and enhance insulin action and compounds identified by the method.
- Insulin is a hormone that is necessary for normal carbohydrate, protein, and fat metabolism in mammals. People with insulin-dependent (Type I) diabetes mellitus do not produce enough insulin of this hormone to sustain life and, therefore, depend on exogenous insulin for survival. In contrast, individuals with non- insulin-dependent (Type II) diabetes are not dependent on exogenous insulin for survival. However, over time, many of individuals with type II diabetes show decreased insulin production, which requires supplemental insulin for adequate blood glucose control, especially during times of stress or illness. An exogenous insulin regimen is often required in the treatment of secondary diabetes, i.e., diabetes occurring in relation to other disease states such as pancreatic disease. Insulin is also used in some cases of gestational diabetes to obtain optimum blood glucose control.
- the conventional route of insulin administration is via a needle and syringe.
- Continuous subcutaneous insulin infusion with an infusion pump is an alternative to conventional injection therapy for achieving normalized levels of blood glucose.
- Insulin initiates its metabolic and growth promoting effects upon binding to its tetrameric receptor. The binding activates a kinase in the beta -subunit, which catalyzes the intramolecular autophosphorylation of specific tyrosine residues of its own ⁇ -subunits. Autophosphorylation enhances tyrosine kinase activity toward other protein substrates.
- insulin receptor tyrosine kinase activity is essential for many, if not all of the biological effects of insulin.
- the precise biochemical mechanisms linking receptor kinase-mediated tyrosine phosphorylation to the regulation of cellular metabolic pathways are not completely defined.
- the instant invention is a novel assay to identify insulin mimetic and enhancer compounds.
- the assay is designated as the Insulin Mimetic and Enhancer ⁇ s ay.
- the purpose of the IMA-II is to discover nonpeptide, small molecules that may be developed into insulin mimetic and enhancer agents.
- the assay is based on insulin receptor tyrosine phosphorylation, and activation of the receptor tyrosine kinase events immediately downstream of insulin stimulation.
- Chinese Hamster Ovary (CHO) cells expressing human insulin receptor are plated and treated with insulin or test agents.
- CHO.T cells are one type of CHO cells that express human insulin receptor. The treated cells are lysed, and the insulin receptor is purified.
- the level of tyrosine phosphorylation of the receptor is determined using an anti- phosphotyrosine antibody conjugated to alkaline phosphatase and its chromogenic substrate.
- the insulin receptor tyrosine kinase activity (IRTK) is determined using an exogenous substrate and ⁇ -32p-ATP. The assay facilitates rapid screening and high throughput of test compounds.
- the invention relates to insulin mimetic and enhancer and enhance agents and more specifically to methods of identifying compounds that mimic and enhance insulin action and compounds identified by the method.
- FIG 1 shows the scheme of insulin mimetic and enhancer assay.
- Figure 2 shows the activation of IRTK by insulin in CHO.T cells.
- Figure 3 shows the activation of IRTK by a natural product (N-400306).
- Figure 4 shows the enhancement of insulin stimulation of IRTK by a natural product (N-400306).
- the invention relates to insulin mimetic and enhancer agents and more specifically to methods of identifying compounds that mimic and enhance insulin action and compounds identified by the method. More specifically, the instant invention is a novel assay to identify insulin mimetic and enhancer compounds.
- the assay is designated as the Insulin Mimetic and Enhancer Assay.
- the purpose of the assay is to discover nonpeptide, small molecules that may be developed into insulin mimetic and enhancing agents.
- the assay is based on insulin receptor tyrosine phosphorylation, and activation of the receptor tyrosine kinase events immediately downstream of insulin stimulation.
- Chinese Hamster Ovary (CHO) cells expressing human insulin receptor (CHO-T) are plated and treated with insulin or test agents.
- the treated cells are lysed, and the insulin receptor is purified.
- the level of tyrosine phosphorylation of the receptor is determined using anti-phosphotyrosine antibody conjugated to alkaline phosphatase and its chromogenic substrate.
- the IRTK activity is determined using an exogenous substrate and ⁇ -32p-ATP.
- the assay is also performed by treating the cells with test agents in the presence of sub-maximal concentration of insulin, in an effort to identify insulin sensitigers. The assay facilitates rapid screening and high throughput of test compounds.
- An insulin-related disease is a disease, disorder, or condition in which some aspect of insulin expression, metabolism, or action is disrupted or, a disease in which insulin action contributes to the disease.
- An insulin resistant disease is any disease, disorder, or condition in which a normal amount of insulin results in a less than normal biological response. Examples of insulin- deficient diseases include Type I or insulin-dependent diabetes. Examples of insulin resistant diseases include Type II diabetes, obesity, age-related insulin resistance, and insulin resistance that arises secondary to infections, hormonal disorders, or other causes.
- the invention includes a method of assaying an effect of a therapeutic agent on activation of insulin signal transduction in cells.
- the method includes administering the agent to a test organism, e.g., a cultured cell or a mammal, and measuring the effect of the drug on an aspect of insulin receptor metabolism, e.g., measuring the level of the insulin receptor phosphorylation.
- a change in an aspect of insulin receptor metabolism indicates an effect of the agent.
- the invention includes a method of assaying an effect of a therapeutic agent which alters the ability of a tyrosine kinase to phosphorylate a substrate.
- the method includes administering the drug to a test organism, e.g., a cultured cell or a mammal, and measuring the level of phosphorylation of a substrate.
- the invention further includes a method of treating a mammal e.g.. a human, suffering from a disease caused by insulin deficiency or insulin resistance, e.g., Type I and Type II diabetes mellitus.
- the method includes administering to the mammal a therapeutical ly effective amount of a therapeutic agent, e.g., agent which alters an aspect of the metabolism of insulin receptor, e.g., the level of insulin receptor phosphorylation, e.g., by increasing the activity of a kinase or decreasing the activity of a phosphatase.
- a therapeutic agent e.g., agent which alters an aspect of the metabolism of insulin receptor, e.g., the level of insulin receptor phosphorylation, e.g., by increasing the activity of a kinase or decreasing the activity of a phosphatase.
- Methods of the invention also allow the treatment of a variety of diseases, e.g., insulin related diseases, insulin resistant diseases, diseases characterized by abnormal cellular proliferation, and diseases caused by the phosphorylation of a substrate by a tyrosine kinase, by intervening in aspects of insulin receptor metabolism.
- diseases e.g., insulin related diseases, insulin resistant diseases, diseases characterized by abnormal cellular proliferation, and diseases caused by the phosphorylation of a substrate by a tyrosine kinase, by intervening in aspects of insulin receptor metabolism.
- the present invention provides methods of identifying compounds that interact with insulin receptor.
- Methods of identifying compounds are exemplified by an assay, comprising:
- the present invention is also directed to methods for screening for compounds which modulate the expression of DNA or RNA encoding genes regulated by insulin or which modulate the function of insulin regulated proteins.
- Compounds which modulate these activities may be DNA, RNA, peptides, proteins, or non- proteinaceous organic molecules.
- Compounds may modulate by increasing or attenuating the expression of DNA or RNA encoding genes regulated by insulin or the function of insulin regulated protein.
- Compounds that modulate the expression of DNA or RNA encoding genes regulated by insulin or the function of insulin regulated protein may be detected by a variety of assays.
- the assay may be a simple "yes/no" assay to determine whether there is a change in expression or function.
- the assay may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample.
- Kits containing the compounds that modulate DNA, RNA, antibodies to insulin regulated protein or insulin regulated protein may be prepared. Such kits are useful for a variety of purposes including but not limited to forensic, taxonomic or epidemiological studies.
- Pharmaceutically useful compositions comprising modulators of insulin activity may be formulated according to known methods such as by the admixture of a pharmaceutically acceptable carrier. Examples of such carriers and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the protein, DNA, RNA, or modulator.
- compositions of the invention are administered to an individual in amounts sufficient to treat or diagnose disorders.
- the effective amount may vary according to a variety of factors such as the individual's condition, weight, sex and age. Other factors include the mode of administration.
- compositions may be provided to the individual by a variety of routes such as subcutaneous, topical, oral and intramuscular.
- chemical derivative describes a molecule that contains additional chemical moieties which are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, abso ⁇ tion, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.
- the present invention also has the objective of providing suitable topical, oral, systemic and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.
- the compositions containing compounds identified according to this invention as the active ingredient can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for administration.
- the compounds can be administered in such oral dosage forms as tablets, capsules (each including timed release and sustained release formulations), pills, powders, granules, elixirs, tinctures, solutions, suspensions, syrups and emulsions, or by injection.
- they may also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, topical with or without occlusion, or intramuscular form, all using forms well known to those of ordinary skill in the pharmaceutical arts.
- compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
- compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in that art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- the active agents can be administered concurrently, or they each can be administered at separately staggered times.
- the dosage regimen utilizing the compounds of the present invention is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound thereof employed.
- a physician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
- Optimal precision in achieving concentrations of drug within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
- the CHO.T cells of the present invention are available from Dr.
- cell lines similar to the CHO.T cells used herein may be prepared by one skilled in the art.
- NIH3T3 cells, COS cells, Rat-1 cells and other appropriate fibroblasts transfected with cDNA encoding human insulin receptor can also be used in this assay.
- the present invention relates to novel modalities for treatment of diabetes, and other diseases caused by dysfunctional signal transduction by receptor type tyrosine kinases. in particular the insulin receptor.
- the present invention further relates to methods for screening and identifying compounds capable of modulating the activity of insulin receptor tyrosine kinases.
- Such compounds may be insulin mimetic or sensitizer, by interaction directly or indirectly with the receptor (e.g., through inhibition of insulin receptor specific tyrosine phosphatase).
- Such compounds may be used in the treatment of diabetes and other diseases mediated by the insulin receptor type tyrosine kinases.
- Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. The process is generally imitated by the binding of extracellular factors (such as hormones and growth factors) to membrane receptors on the cell surface.
- extracellular factors such as hormones and growth factors
- the biochemical pathways through which signals are transmitted within cells comprise a circuitry of directly or functionally connected interactive proteins. Each protein component in a pathway integrates signals from upstream activators and passes them onto various downstream effector proteins.
- the phosphorylation state of a protein may affect its conformation and/or enzymic activity as well as its cellular location.
- the phosphorylation state of a protein is modified through the reciprocal actions of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs).
- PTKs protein tyrosine kinases
- PTPs protein tyrosine phosphatases
- Protein tyrosine kinases comprise a large family of transmembrane as well as cytoplasmic enzymes with multiple functional domains (Taylor et al., 1992 Ann. Rev. Cell Biol. 8:429-62).
- RPTKs receptor protein tyrosine kinase
- Receptor dimerization stabilizes the interactions between adjacent cytoplasmic domains, and activates the intrinsic kinase activity of the receptor. Once activated, the receptor self-phosphorylates (autophosphorylation or transphosphorylation) on specific tyrosine residues in the cytoplasmic domain (Schlessinger, 1988, Trends Biochem., Sci. 13:443-7, Schlessinger and Ullrich, 1992, Neuron, 9:383-91 , and references therein). In case of insulin receptor-type RPTKs, the receptor exists naturally as a dimer, undergoing a conformational change and autophosphorylation upon ligand binding.
- RPTKs assume a key role in signal transduction, the part played by phosphatases remains poorly understood.
- PTP protein tyrosine phosphatases
- the protein tyrosine phosphatases comprise a family of transmembrane and cytoplasmic enzymes.
- RPTKs play a triggering role in signal transduction, while RPTPs guarantee that the trigger is reset, thereby serving to deactivate the pathway.
- the PTP specific for insulin receptor is not defined at present.
- the insulin receptor (IR) (Ebina et al, 1985, Cell, 40, 747- 758; Ullrich et al, 1985, Nature 313:756-61 ) is the prototype for a family of RPTKs structurally defined as a heterotetrameric species of two ⁇ and two ⁇ subunits.
- Other members of the insulin receptor-type protein tyrosine kinase (IR-PTK) family include the receptor for insulin-like growth factor I (IGF-1 R; Ullrich et al, 1986, EMBO J 5:2503-12) and the insulin related receptor (IRR; Zhang et al, 1992, J. Biol. Chem. 267: 18320-8), the ligand(s) for which are at present unknown.
- Insulin binding to the insulin receptor triggers a variety of metabolic and growth promoting effects. Metabolic effects include glucose transport, biosynthesis of glycogen and fats, inhibition of triglyceride breakdown, and growth promoting effects include DNA synthesis, cell division and differentiation. It is known that some of these biological effects of insulin can be mimicked by vanadium salts such as vanadates and pervanadates. However, this class of compounds appears to inhibit phosphotyrosine phosphatases generally, and are potentially toxic because they contain heavy metal (U.S. Patent No. 5.155,031 ; Fantus et al, 1989, Biochem., 28:8864-71 ; Swamp et al, 1982, Biochem. Biophys. Res. Commun. 107:1 104-9).
- Diabetes mellitus is a heterogeneous primary disorder of carbohydrate metabolism with multiple etiologic factors that generally involve insulin deficiency or insulin resistance or both.
- Type I or juvenile onset, or insulin-dependent diabetes mellitus
- Type II or adult onset, or non-insulin-dependent diabetes mellitus
- Insulin resistance can be due to insufficient insulin receptor expression, reduced insulin-binding affinity, or any abnormality at any step along the insulin signaling pathway.
- diabetes is probably between 2 and 4 per cent, with Type I comprising 7 to 10 per cent of all cases. Secondary complications of diabetes have serious clinical implications. Approximately 25 per cent of all new cases of end-stage renal failure occur in patients with diabetes. About 20,000 amputations (primarily of toes, feet, and legs) are carried out in patients with diabetes, representing approximately half of the nontraumatic amputations performed in the United States. Furthermore, diabetes is the leading cause of new cases of blindness, with approximately 5000 new cases occurring each year.
- Insulin is the primary mode of therapy in all patients with Type I and in many with Type II diabetes.
- the regimen can be more or less intensive.
- the most intensive method consists of constant insulin delivery into a subcutaneous site in the abdominal wall via an open loop delivery device consisting of a small insulin pump that must be worn by the patient essentially 24 hours a day.
- Oral hypoglycemic agents such as sulfonylureas are effective in Type II patients but approximately 10 to 20 percent of patients do not respond or cases to respond 12-24 months after beginning treatment.
- the present invention relates to novel modalities for treatment of diabetes, and other diseases caused by dysfunctional signal transduction by the insulin receptor (IR) class of protein tyrosine kinases.
- the present invention further relates to methods for screening and identifying compounds which mimic or enhance the ability of insulin to activate IRTK (insulin mimetic and enhancer assay) and thus have uses in the treatment of diabetes and other diseases.
- the present invention relates to novel modalities for the treatment of diabetes, and other diseases caused by dysfunctional signal transduction by insulin receptor type protein tyrosine kinases (IR- PTKs).
- IR- PTKs insulin receptor type protein tyrosine kinases
- signal transduction is not limited to transmembrane signaling, and includes the multiple pathways that branch off throughout the cell and into the nucleus. Within each individual circuit of the pathway, protein tyrosine kinases and tyrosine phosphatases carry out a series of phosphorylation and dephosphorylation steps which serve to propagate or terminate the signal.
- the present invention involves the use of compounds, antibodies, nucleic acid molecules or other approaches to modulate the activity of IRTK targets and, therefore, affect signal transduction.
- compositions of the present invention in particular, those formulated as solutions, may be administered parenterally. such as by intravenous injection.
- pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended pu ⁇ ose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- the preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.
- compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- compositions for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl- cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this pu ⁇ ose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC50 as determined in cell culture (i.e.. the concentration of the test compound which achieves a half -maximal inhibition of the PTP activity). Such information can be used to more accurately determine useful doses in humans.
- a therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms or a prolongation of survival in a patient.
- Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Compounds which exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al, 1975, in "The Pharmacological Basis or Therapeutics", Ch. 1 PD.
- the cell lines that express the insulin receptor may be used to screen for molecules that modulate the tyrosine kinase activity.
- molecules may include small organic or inorganic compounds, antibodies, peptides, or other molecules that directly activate IRTK by inducing conformations charge and autophosphorylate of the receptor, or indirectly activate IRTK through inhibitor of the IR specific phosphate.
- Synthetic compounds, natural products, and other sources of potentially biologically active materials can be screened in a number of ways.
- the ability of a test molecule to modulate the activity of IRTK hence signal transduction, may be measured using standard biochemical techniques.
- Ligand binding to its cellular receptor may, via signal transduction pathways, affect a variety of cellular processes.
- Cellular processes under the control of insulin signaling pathway may include, but are not limited to, normal cellular functions such as carbohydrate metabolism, proliferation, differentiation, maintenance of cell shape, and adhesion, in addition to abnormal or potentially deleterious processes such as apoptosis, loss of contact inhibition, blocking of differentiation or cell death.
- the qualitative or quantitative observation and measurement of any of the described cellular processes by techniques known in the art may be advantageously used as a means of scoring for signal transduction in the course of screening.
- the present invention includes a method for identifying a compound which is capable of modulating insulin receptor-type protein kinase IR-PTK signal transduction, comprising:
- step (b) incubating the mixture of step (a) for an interval sufficient for the compound to stimulate IRTK enzymatic activity or the signal transduction; (c) measuring the IRTK enzymatic activity or the signal transduction;
- IR-PTK signal transduction activity may be measured by standard biochemical techniques or by monitoring the cellular processes controlled by the signal.
- the test molecule is added to a culture medium of IR expressing cells, IR is then immunopurified and IRTK activity measured. Where the test molecule is intended to mimic ligand stimulation, the assay is conducted in the absence of insulin. Where the test molecule is intended to enhance insulin activity, the test is conducted in the presence of insulin.
- the kinase activity is determined in the presence of ATP and a substrate and results are compared to those obtained for controls i.e., reaction mixtures not exposed to the test molecule.
- the present invention also includes a method for identifying and isolating a nucleic acid molecule encoding a gene product which is capable of modulating IR-PTK signal transduction, comprising:
- the above method may further include the step of:
- step (e) selecting and culturing the cells identified in step (d), recovering the nucleic acid molecule, thereby isolating the nucleic acid molecule.
- nucleic acid molecule a naturally occurring or recombinantly generated nucleic acid molecule containing a nucleotide sequence operatively associated with an element that controls expression of the nucleotide sequence.
- An expression library may be created by introducing into host cells a pool of different nucleic acid molecules encoding different gene products. The host cells may be genetically engineered to coexpress IR and other relevant proteins. Such a gene library may be screened by standard biochemical techniques or by monitoring the cellular processes controlled by the signal. This approach is especially useful in identifying other native signaling molecules that are also involved in the signaling pathway.
- CHO.T cells which overexpress human insulin receptor, were a gift of Dr. R. A. Roth, Stanford University.
- CHO.T cells (approximately 1.5 x 10-5 cells/well) were cultured in Hams F12 medium supplemented with 10% fetal calf serum, fungizone, penicillin and streptomycin. The 96-well plates were incubated for approximately 24 h at 37°C, which is when the cells reached confluency. The cells were washed with phosphate buffered saline (PBS) three times and then incubated in serum-free medium for 3 h at 37°C. Insulin or test compounds were added to the wells, and the cells were incubated for an additional 20 min at 37°C.
- PBS phosphate buffered saline
- the cells were washed three times with PBS and lysates were prepared.
- the lysates were transferred to a second 96 well plate.
- the wells of the second plate had been precoated with monoclonal anti-insulin receptor antibody.
- Antibody was diluted to a final concentration of approximately 4 mcg/mL in 20 mM NaHC03, pH 9.6. Approximately 50 mcL of diluted antibody solution was added to each well.
- the lysates were incubated for 16 h at 4°C to immunopurify the insulin receptor.
- the washed plates are incubated for 5 h at 4°C with monoclonal antiphosphotyrosine antibody conjugated to alkaline phosphatase (Transduction Laboratories). The unbound antibody is removed and chromogenic substrate of alkaline phosphotase is added to the wells. Signals are detected at 405 nm with a microtiter plate reader.
- Compounds identified by the method of Example 1 are formulated into pharmaceutical compositions according to standard methods.
- the compounds or pharmaceutical compositions are used either alone or in combination with other compounds or compositions for the treatment of animals (including humans) in need of treatment.
- Conditions requiring treatment include but are not limited to diabetes, obesity, regulation of appetite, congestive heart failure, anxiety, hypertension, cocaine withdrawal, congestive heart failure, memory enhancement, cardiac and cerebral vasospasm, pheochromocytoma and ganglioneuroblastoma, and Huntington's, Alzheimer's and Parkinson's diseases.
- Animals having a condition, the condition being characterized by factors selected from altered levels of insulin or altered activities of insulin, which are treated with compounds or derivatives of compounds identified by the screening method or pharmaceutical compositions comprising the compounds or derivatives of compounds identified by the screening method.
- CHO.T cells which overexpress human insulin receptor, were a gift of Dr. R. A. Roth, Stanford University.
- CHO.T cells (approximately 1.5 x 10-5 cells/well) were cultured in Hams F12 medium supplemented with 10% fetal calf serum, fungizone, penicillin and streptomycin. The 96-well plates were incubated for approximately 24 h at 37°C. which is when the cells reached confluency. The cells were washed with phosphate buffered saline (PBS) three times and then incubated in serum-free medium for 3 h at 37°C. Insulin or test compounds were added to the wells, and the cells were incubated for an additional 20 min at 37°C.
- PBS phosphate buffered saline
- the cells were washed three times with PBS and lysates were prepared.
- the lysates were transferred to a second 96 well plate.
- the wells of the second plate had been precoated with monoclonal anti-insulin receptor antibody.
- Antibody was diluted to a final concentration of approximately 4 mcg/mL in 20 mM NaHC ⁇ 3, pH 9.6. Approximately 1 0 mcL of diluted antibody solution was added to each well.
- the lysates were incubated for 16 h at 4°C to immunopurify the insulin receptor.
- the IRTK To determine the IRTK, twenty microliters of the kinase reaction mixture (50 mM Hepes, pH 7.6, 150 mM NaCl, 5 mM MgCl2, 5 mM MnCl2, 0.1 % Triton X-100, 1 mg/ml poly(Glu:Tyr)(4: l ), 2 ⁇ Ci of carrier-free [ ⁇ -32p]ATP) was added to each well of the 96-well plates and the incubation was continued at 25 °C for 40 min. The reaction was terminated by addition of 50 ⁇ l 100 mM phosphoric acid. The mixture was transferred to Multiscreen PH plates and washed. The radioactivities associated with the wells were determined using a Topcount. The IRTK activities stimulated by test agents were compared to that stimulated by insulin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8529629A JPH11503519A (ja) | 1995-03-31 | 1996-03-27 | インシュリンの擬似剤及び増強剤のアッセイ |
EP96910609A EP0817967A4 (fr) | 1995-03-31 | 1996-03-27 | Methode d'identification de composes imitant et amplifiant l'action de l'insuline |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41497695A | 1995-03-31 | 1995-03-31 | |
US08/414,976 | 1995-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996030762A1 true WO1996030762A1 (fr) | 1996-10-03 |
Family
ID=23643820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/004226 WO1996030762A1 (fr) | 1995-03-31 | 1996-03-27 | Methode d'identification de composes imitant et amplifiant l'action de l'insuline |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0817967A4 (fr) |
JP (1) | JPH11503519A (fr) |
CA (1) | CA2216806A1 (fr) |
WO (1) | WO1996030762A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998032017A3 (fr) * | 1997-01-15 | 1999-02-25 | Terrapin Tech Inc | Modulateurs de l'activite du recepteur d'insuline |
US6660763B2 (en) | 1996-11-13 | 2003-12-09 | Sugen, Inc. | Bis-indolylquinone compounds |
WO2003031472A3 (fr) * | 2001-10-09 | 2004-03-25 | Nutricia Nv | Sequences d'acides amines insulinomimetiques |
US6750240B2 (en) | 1996-11-13 | 2004-06-15 | Sugen, Inc. | Methods of using bis-indolylquinones |
US6884597B1 (en) | 1998-01-20 | 2005-04-26 | Medical & Biological Laboratories, Co., Ltd. | Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes |
USRE38915E1 (en) | 1997-01-15 | 2005-12-06 | Telik, Inc. | Nonpeptide insulin receptor agonists |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002055664A2 (fr) * | 2001-01-12 | 2002-07-18 | Exelixis, Inc. | Modulation de la signalisation du recepteur de l'insuline |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536517A (en) * | 1983-04-25 | 1985-08-20 | American Cyanamid Company | Method of treating diabetes mellitus using arylglyoxals |
US5405855A (en) * | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019570A1 (fr) * | 1994-01-14 | 1995-07-20 | Genentech, Inc. | Antagonistes de l'inhibiteur de l'activite tyrosine kinase du recepteur de l'insuline |
US5861266A (en) * | 1994-02-28 | 1999-01-19 | New York University | Treatment of diabetes mellitus and insulin receptor signal transduction |
WO1995023231A1 (fr) * | 1994-02-28 | 1995-08-31 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Lignees cellulaires destinees a l'identification de substances affectant la transduction du signal induit par le recepteur d'insuline |
US5652221A (en) * | 1994-11-07 | 1997-07-29 | The University Of Virginia Patent Foundation | Method of treating defective glucose metabolism using synthetic insulin substances |
-
1996
- 1996-03-27 EP EP96910609A patent/EP0817967A4/fr not_active Withdrawn
- 1996-03-27 WO PCT/US1996/004226 patent/WO1996030762A1/fr not_active Application Discontinuation
- 1996-03-27 JP JP8529629A patent/JPH11503519A/ja active Pending
- 1996-03-27 CA CA002216806A patent/CA2216806A1/fr not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536517A (en) * | 1983-04-25 | 1985-08-20 | American Cyanamid Company | Method of treating diabetes mellitus using arylglyoxals |
US5405855A (en) * | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
Non-Patent Citations (3)
Title |
---|
BIOCHEMICAL JOURNAL, Vol. 268, issued 1990, BRINDLE et al., "Anti-(Insulin Receptor) Monoclonal Antibody-Stimulated Tyrosine Phosphorylation in Cells Transfected with Human Insulin Receptor cDNA", pages 615-620. * |
See also references of EP0817967A4 * |
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 16, issued 05 June 1990, G. STEELE-PERKINS et al., "Insulin-Mimetic Anti-Insulin Receptor Monoclonal Antibodies Stimulate Receptor Kinase Activity in Intact Cells", pages 9458-9463. * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660763B2 (en) | 1996-11-13 | 2003-12-09 | Sugen, Inc. | Bis-indolylquinone compounds |
US6750240B2 (en) | 1996-11-13 | 2004-06-15 | Sugen, Inc. | Methods of using bis-indolylquinones |
WO1998032017A3 (fr) * | 1997-01-15 | 1999-02-25 | Terrapin Tech Inc | Modulateurs de l'activite du recepteur d'insuline |
USRE38915E1 (en) | 1997-01-15 | 2005-12-06 | Telik, Inc. | Nonpeptide insulin receptor agonists |
USRE39866E1 (en) | 1997-01-15 | 2007-10-02 | Telik, Inc. | Nonpeptide insulin receptor agonists |
US6884597B1 (en) | 1998-01-20 | 2005-04-26 | Medical & Biological Laboratories, Co., Ltd. | Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes |
WO2003031472A3 (fr) * | 2001-10-09 | 2004-03-25 | Nutricia Nv | Sequences d'acides amines insulinomimetiques |
Also Published As
Publication number | Publication date |
---|---|
JPH11503519A (ja) | 1999-03-26 |
EP0817967A1 (fr) | 1998-01-14 |
EP0817967A4 (fr) | 2000-05-17 |
CA2216806A1 (fr) | 1996-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ross et al. | Chemistry and biochemistry of type 2 diabetes | |
Gottschalk et al. | Signaling mechanisms mediating BDNF modulation of synaptic plasticity in the hippocampus | |
Cui et al. | The role of AMPK in macrophage metabolism, function and polarisation | |
Hajduch et al. | Serotonin (5-hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle | |
Rockey | The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide | |
Huang et al. | Insulin enhances mitochondrial inner membrane potential and increases ATP levels through phosphoinositide 3-kinase in adult sensory neurons | |
US7344843B2 (en) | Agonists and antagonists of prolixin for the treatment of metabolic disorders | |
WO1996040109A1 (fr) | Procedes d'inhibition de l'activite de phosphatase, et de traitement de pathologies associees a l'aide de naphtopyrones et de leurs derives | |
Qu et al. | Theaflavin promotes mitochondrial abundance and glucose absorption in myotubes by activating the CaMKK2-AMPK signal axis via calcium-ion influx | |
Beg et al. | PPP2R5B, a regulatory subunit of PP2A, contributes to adipocyte insulin resistance | |
US5861266A (en) | Treatment of diabetes mellitus and insulin receptor signal transduction | |
RU2417078C2 (ru) | Новое применение агонистов печеночного рецептора х | |
WO1996030762A1 (fr) | Methode d'identification de composes imitant et amplifiant l'action de l'insuline | |
Gezginci-Oktayoglu et al. | 4-Methlycatechol prevents NGF/p75NTR-mediated apoptosis via NGF/TrkA system in pancreatic β cells | |
Small et al. | Phenotypic screening for small molecules that protect β-cells from glucolipotoxicity | |
SENTHIL et al. | Angiotensin II inhibits insulin-stimulated phosphorylation of eukaryotic initiation factor 4E-binding protein-1 in proximal tubular epithelial cells | |
US20020022023A1 (en) | Treatment of diabetes mellitus and insulin receptor signal transduction | |
Yamaguchi et al. | The behavior of dihydropyrazine with DNA strand-breakage activity in vivo | |
Andreozzi et al. | Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo | |
US20120264796A1 (en) | Methods for modulating circadian rhythms | |
US20030095983A1 (en) | Use of corticotroph-derived glycoprotein hormone to induce lipolysis | |
AU2005251741B2 (en) | Insulin-independent, bone morphogenetic protein (BMP)-mediated uptake of blood glucose by peripheral cells and tissues | |
Yu et al. | The upregulating effect of insulin and vanadate on cell surface insulin receptors in rat adipocytes is modulated by glucose and energy availability | |
US7276342B2 (en) | Xobesin agonists and antagonists for the treatment of metabolic disorders | |
Chao et al. | Interleukin-4 restores insulin sensitivity in insulin-resistant osteoblasts by increasing the expression of insulin receptor substrate 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996910609 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 913917 Date of ref document: 19970923 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2216806 Country of ref document: CA Ref country code: CA Ref document number: 2216806 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1996 529629 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996910609 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996910609 Country of ref document: EP |